A Phase 4 interventional study of Intra-nasal Dexmedetomidine and Oral Midazolam in Pediatric Delirium, sponsored by University of Massachusetts, Worcester. Enrolling by invitation at 1 site in United States. Open to participants aged 3 Months to 9 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by University of Massachusetts, Worcester · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.
Among the 78 studies testing dexmedetomidine in Delirium, this one is the 49th largest by planned enrollment, is one of 7 that started in 2021, is one of 35 in phase 4, reaches primary completion later than 9 of the 16 other live ones, and was the 54th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 60+
Tanta University · Sites in Egypt
Ages 21+
Tanta University · Sites in Egypt
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Douglas Fraser · Sites in Canada
Ages 1 mo–17 yrs
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 3 Months to 9 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 12 · Phase 4 35
First in 2004; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 111 across 551 interventional studies indexed under Delirium.
Median enrollment 98 across the 78 interventional studies. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 78 have an industry lead sponsor. The 10 most frequent:
University of Massachusetts, Worcester is the lead sponsor of 291 studies on the registry; 50 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
University of Massachusetts, Worcester has 2 studies filed under Delirium — fewer than ten, so there is no comparison to draw.
3 of the studies testing dexmedetomidine in Delirium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06192615Phase 3Massachusetts General HospitalMinimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II) | 2027-10-31 |
| NCT04669457University of Massachusetts, WorcesterPediatric Delirium | 2027-04-05 |
| NCT07781462Alexandria UniversityIntravenous Infusion of Low Dose Ketamine Versus Dexmedetomedine for Delirium Treatment in Acute Heart Failure | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies testing dexmedetomidine in Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preventing emergent delirium in pediatric ambulatory surgery through preoperative use of intra-nasal Dexmedetomidine and oral Midazolam.
Pediatric ambulatory patients will randomly be allocated to one of two groups. Group A which will receive Dexmedetomidine intra-nasally at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room or Group B which will receive Midazolam orally at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room. Each subject will receive a Drug Acceptance scale, and Parental Separation Anxiety Scale (PSAS) mask Acceptance Scale to identify the differences in markers associated with pediatric delirium. End tidal Sevoflurane value during the surgery and at the time when patient leaves the OR, amount and dose of oral/rectal acetaminophen given in PACU, child's behavior for 48 hours post-operatively, and documented intake of oral analgesics will be collected to identify the reduced need for post-operative analgesia and behaviors associated with extended pediatric delirium.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
Drug: Intra-nasal Dexmedetomidine
Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
Drug: Oral Midazolam
Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
Also known as: Precedex
Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
Also known as: Midazolam
Time to onset of pediatric delirium
Time from when the patient is woken from anesthesia to the onset of delirium.
Time frame: Zero minutes to 48 hours
Time to offset of pediatric delirium
Time from onset of delirium to the offset of delirium.
Time frame: Zero minutes to 48 hours
Duration of pediatric delirium
Total time patient experiences delirium
Time frame: Zero minutes to 48 hours
Drug Acceptance
The willingness of the subject to take the drug was assessed in the pre-operative area
Time frame: 10-25 minutes prior to surgery
Parental Separation Anxiety Scale (PSAS)
Anxiety score was determined when the child was separated from the parents according to four levels.
Time frame: 0-48 hours
Mask Acceptance Scale
The child's acceptance of the mask by the anesthesiologist was rated as follows.
Time frame: 1-10 minutes prior to surgery
End tidal Sevoflurane value
During the surgery and at the time when patient leaves the OR End tidal Sevoflurane value will be documented.
Time frame: 0-12 hours
Rescue analgesia in PACU
The amount and dose of oral/rectal acetaminophen given in PACU was recorded.
Time frame: 0-6 hours post surgery
Home Behavior Analysis
The child's parents were given a diary to document their behavior for 48 hours post-operatively at home.
Time frame: 12-48 hours
Oral analgesic use
Document intake of oral analgesics like acetaminophen or ibuprofen
Time frame: Two days post-operative
Plan to share: No — Data will be shared via publication as group data.
No publications or documents are linked to this record.
Started Apr 2021 (actual). Primary completion is estimated for Apr 2027, 71 months after the start.
Of 40 non-industry phase 4 interventional studies under Delirium, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 62. This study's planned 71 months is above that.
Counting every sponsor, half of 40 studies reached it within 44 months; a quarter within 25 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
University of Massachusetts, Worcester →